Dutta Tumpa, Kudva Yogish C, Persson Xuan-Mai T, Schenck Louis A, Ford G Charles, Singh Ravinder J, Carter Rickey, Nair K Sreekumaran
Divisions of Endocrinology and Endocrine Research Unit (Y.C.K., K.S.N.) and Biomedical Statistics and Informatics (L.A.S., R.C.), Mayo Clinic Metabolomics Resource Core (T.D., X.-M.T.P., G.C.F., K.S.N.), and Department of Laboratory Medicine and Pathology (R.J.S.), Mayo Clinic, Rochester, Minnesota 55905.
J Clin Endocrinol Metab. 2016 Mar;101(3):1023-33. doi: 10.1210/jc.2015-2640. Epub 2016 Jan 21.
Poor glycemic control in individuals with type 1 diabetes (T1D) is associated with both micro- and macrovascular complications, but good glycemic control does not fully prevent the risk of these complications.
The objective of the study was to determine whether T1D with good glycemic control have persistent abnormalities of metabolites and pathways that exist in T1D with poor glycemic control.
We compared plasma metabolites in T1D with poor (glycated hemoglobin ≥ 8.5%, T1D[-] and good (glycated hemoglobin < 6.5%, T1D[+]) glycemic control with nondiabetic controls (ND).
The study was conducted at the clinical research unit.
T1D with poor (n = 14), T1D(-) and good, T1D(+) (n = 15) glycemic control and matched (for age, sex, and body mass index) ND participants were included in the study.
INTERVENTION(S): There were no intervention.
MAIN OUTCOME MEASURE(S): Comparison of qualitative and quantitative profiling of metabolome was performed.
In T1D(-), 347 known metabolites belonging to 38 metabolic pathways involved in cholesterol, vitamin D, tRNA, amino acids (AAs), bile acids, urea, tricarboxylic acid cycle, immune response, and eicosanoids were different from ND. In T1D(+),154 known metabolites belonging to 26 pathways including glycolysis, gluconeogenesis, bile acids, tRNA biosynthesis, AAs, branch-chain AAs, retinol, and vitamin D metabolism remained altered from ND. Targeted measurements of AA metabolites, trichloroacetic acid, and free fatty acids showed directional changes similar to the untargeted metabolomics approach.
Comprehensive metabolomic profiling identified extensive metabolomic abnormalities in T1D with poor glycemic control. Chronic good glycemic control failed to normalize many of these perturbations, suggesting a potential role for these persistent abnormalities in many complications in T1D.
1型糖尿病(T1D)患者血糖控制不佳与微血管和大血管并发症均相关,但良好的血糖控制并不能完全预防这些并发症的风险。
本研究的目的是确定血糖控制良好的T1D患者是否存在血糖控制不佳的T1D患者中持续存在的代谢物和代谢途径异常。
我们将血糖控制不佳(糖化血红蛋白≥8.5%,T1D[-])和血糖控制良好(糖化血红蛋白<6.5%,T1D[+])的T1D患者的血浆代谢物与非糖尿病对照(ND)进行了比较。
该研究在临床研究单位进行。
血糖控制不佳(n = 14)、T1D(-)和良好、T1D(+)(n = 15)的T1D患者以及匹配(年龄、性别和体重指数)的ND参与者被纳入研究。
无干预措施。
进行代谢组的定性和定量分析比较。
在T1D(-)中,347种已知代谢物属于38条代谢途径,涉及胆固醇、维生素D、转运RNA、氨基酸(AA)、胆汁酸、尿素、三羧酸循环、免疫反应和类花生酸,与ND不同。在T1D(+)中,154种已知代谢物属于26条途径,包括糖酵解、糖异生、胆汁酸、转运RNA生物合成、AA、支链AA、视黄醇和维生素D代谢,与ND相比仍有改变。对AA代谢物、三氯乙酸和游离脂肪酸的靶向测量显示出与非靶向代谢组学方法相似的方向性变化。
综合代谢组分析确定了血糖控制不佳的T1D患者存在广泛的代谢组异常。长期良好的血糖控制未能使许多这些扰动恢复正常,表明这些持续异常在T1D的许多并发症中可能起作用。